Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
Jennifer Smith, Loveleen Bansi‐Matharu, Valentina Cambiano, et al.
The Lancet HIV (2023) Vol. 10, Iss. 4, pp. e254-e265
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Predicted dolutegravir resistance in people living with HIV in South Africa during 2020–35: a modelling study
Tom Loosli, Nuri Han, Anthony Hauser, et al.
The Lancet Global Health (2025) Vol. 13, Iss. 4, pp. e698-e706
Closed Access | Times Cited: 3
Community-based active-case finding for tuberculosis: navigating a complex minefield
Peter MacPherson, Kwame Shanaube, Mphatso D. Phiri, et al.
BMC Global and Public Health (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 12
The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery
Mary Henderson, H Schmidt, Lastone Chitembo, et al.
AIDS and Behavior (2023) Vol. 27, Iss. 11, pp. 3755-3766
Open Access | Times Cited: 17
HIV transmission dynamics and population-wide drug resistance in rural South Africa
Steven A. Kemp, Kimia Kamelian, Diego F. Cuadros, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
The long wait for long-acting HIV prevention and treatment formulations
François Venter, Monica Gandhi, Simiso Sokhela, et al.
The Lancet HIV (2024) Vol. 11, Iss. 10, pp. e711-e716
Closed Access | Times Cited: 8
Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension
Moses R. Kamya, Laura B. Balzer, James Ayieko, et al.
The Lancet HIV (2024) Vol. 11, Iss. 11, pp. e736-e745
Closed Access | Times Cited: 8
What will it take for an injectable ARV to change the face of the HIV epidemic in high‐prevalence countries? Considerations regarding drug costs and operations
Gesine Meyer‐Rath, Lise Jamieson, Yogan Pillay
Journal of the International AIDS Society (2023) Vol. 26, Iss. S2
Open Access | Times Cited: 16
Health impact, budget impact, and price threshold for cost-effectiveness of lenacapavir for HIV pre-exposure prophylaxis in eastern and southern Africa: a modelling analysis
Linxuan Wu, David Kaftan, Rachel Wittenauer, et al.
The Lancet HIV (2024)
Open Access | Times Cited: 6
“Men Take Care of Each Other”: Evaluation of a Community-Based Model for Pre-exposure Prophylaxis Services Among Male Bar Patrons in Rural South Africa
Yi‐Ping Phoebe Chen, Sebenzile Nkosi, Anthony P. Moll, et al.
AIDS Patient Care and STDs (2025)
Closed Access
Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir
Michelle L. D’Antoni, Brie Falkard, Kristen Andreatta, et al.
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Long-acting Antiretroviral Agents in the Prevention and Treatment of HIV/AIDS: A Review of Recent Advances in Sub-Saharan Africa
Ekere James Essien, Osaro Mgbere
International Journal of Maternal and Child Health and AIDS (2025) Vol. 14, pp. e003-e003
Open Access
Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men
Philip Wikman‐Jorgensen, Marta Ruiz‐Algueró, Carlos Iniesta, et al.
Enfermedades Infecciosas y Microbiología Clínica (2025)
Closed Access
Preventing HIV in women in Africa
Frances M. Cowan, Maryam Shahmanesh, Paul Revill, et al.
Nature Medicine (2025)
Open Access
Cost thresholds for anticipated long‐acting HIV pre‐exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study
David Kaftan, Monisha Sharma, Danielle Resar, et al.
Journal of the International AIDS Society (2025) Vol. 28, Iss. 2
Open Access
Implementation and resource needs for long‐acting PrEP in low‐ and middle‐income countries: a scoping review
Delivette Castor, Craig J. Heck, Daniela Quigee, et al.
Journal of the International AIDS Society (2023) Vol. 26, Iss. S2
Open Access | Times Cited: 9
Two-drug regimens for the treatment of HIV in Africa
Ivan Mambule, Claire Norcross, Loice Achieng Ombajo, et al.
The Lancet HIV (2024) Vol. 11, Iss. 6, pp. e419-e426
Closed Access | Times Cited: 3
Preference for novel biomedical HIV pre-exposure prophylaxis methods among adolescent girls and young women in Kampala, Uganda: a mixed methods study
Yunia Mayanja, Ivy Kayesu, Onesmus Kamacooko, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access | Times Cited: 3
HIV Pre-Exposure Prophylaxis
Geoffroy Liégeon, Constance Delaugerre, Jean‐Michel Molina
Infectious Disease Clinics of North America (2024) Vol. 38, Iss. 3, pp. 453-474
Closed Access | Times Cited: 3
Dynamic choice HIV prevention intervention at outpatient departments in rural Kenya and Uganda
Catherine A. Koss, James Ayieko, Jane Kabami, et al.
AIDS (2023) Vol. 38, Iss. 3, pp. 339-349
Open Access | Times Cited: 8
Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: A meta-analysis
Andrea Perez Navarro, Cameron T Nutt, Mark J. Siedner, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 2
Global burden of antimicrobial resistance in lower respiratory infections in 2021: a systematic analysis
Xingyu Wan, Raymond Miao, Ning Zhang, et al.
International Journal of Antimicrobial Agents (2024) Vol. 65, Iss. 2, pp. 107431-107431
Closed Access | Times Cited: 2
The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants
Leigh F. Johnson, Landon Myer, Lise Jamieson, et al.
AIDS (2023) Vol. 38, Iss. 4, pp. 589-594
Open Access | Times Cited: 6
Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis
Carey Pike, Elzette Rousseau, Linda‐Gail Bekker
Southern African Journal of HIV Medicine (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis
Andrew Phillips, Loveleen Bansi‐Matharu, Maryam Shahmanesh, et al.
The Lancet Global Health (2023) Vol. 11, Iss. 10, pp. e1648-e1657
Open Access | Times Cited: 5
Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countries
Neil Parkin, P. Richard Harrigan, Seth Inzaule, et al.
PLOS Global Public Health (2023) Vol. 3, Iss. 10, pp. e0001948-e0001948
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top